The Technical AnalystExchange: TWO Sector: Healthcare Industry: Biotechnology
TaiMed Biologics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.48% TWD86.70
America/New_York / 7 mai 2024 @ 01:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 23 670 mill |
| EPS: | -0.760 |
| P/E: | -114.08 |
| Earnings Date: | May 03, 2024 |
| SharesOutstanding: | 273.01 mill |
| Avg Daily Volume: | 2.37 mill |
| RATING 2024-05-07 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -114.08 | sector: PE 34.77 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.96x |
| Company: PE -114.08 | industry: PE 58.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
TWD-24.83 (-128.64%) TWD-111.53 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
TWD 83.32 - 90.08 ( +/- 3.90%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | TWD86.70 (-1.48% ) |
| Volume | 0.737 mill |
| Avg. Vol. | 2.37 mill |
| % of Avg. Vol | 31.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 4147.TWO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
4147.TWO
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.